富马酸丙酚替诺福韦与恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者效果比较研究*

doi:10.3969/j.issn.1672-5069.2024.05.026

摘要/Abstract

摘要： 目的分析比较富马酸丙酚替诺福韦与恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者的疗效。方法 2020年1月～2023年1月我院收治的64例高血清病毒载量(HBVDNA为1×10⁶ IU/mL或以上)的代偿期乙型肝炎肝硬化患者,被随机分为对照组32例和观察组32例,分别给予恩替卡韦和富马酸丙酚替诺福韦治疗,连续治疗观察12个月。使用高效液相色谱分析法检测尿液乳果糖/甘露醇(L/M)比值,采用比色法检测血清D-乳酸,采用紫外比色法检测血清二胺氧化酶(DAO),采用ELISA法检测血清内霉素和白细胞介素-7(IL-7),采用化学发光免疫分析法检测血清降钙素原(PCT),采用免疫荧光定量法检测肝素结合蛋白(HBP)。结果在观察治疗12个月末,两组均获得病毒学和生化学应答,两组血清TBIL、ALT和AST水平无显著性相差(P>0.05);观察组血清DAO、D-乳酸、内霉素和尿L/M比值分别为(2.8±0.6)U/mL、(7.9±1.8)μg/mL、(0.5±0.1)EU/mL和(7.3±1.6)%,与对照组【分别为(3.0±0.5)U/mL、(7.8±2.2)μg/mL、(0.6±0.1)EU/mL和(8.1±1.9)%,P>0.05】比,无显著性差异;观察组血清PCT、HBP和IL-7水平分别为(0.01±0.00)μg/L、(43.1±3.7)ng/mL和(768.9±20.3)pg/mL,与对照组【分别为(0.02±0.01)μg/L、(47.6±3.2)ng/mL和(743.4±21.5)pg/mL,P>0.05】比,无显著性差异。结论应用富马酸丙酚替诺福韦或恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者疗效肯定,对肠道屏障功能无明显的影响。

关键词: 肝硬化, 乙型肝炎, 富马酸丙酚替诺福韦, 恩替卡韦, 高病毒载量, 肠道屏障功能, 治疗

Abstract: Objective The aim of this study was to investigate intestinal barrier function index changes in patients with compensated hepatitis B liver cirrhosis (LC) and high serum viral loads undergoing tenofovir alafenamide fumarate (TAF) or entecavir (ETV) therapy. Methods 64 patients with compensated hepatitis B-induced LC and high serum viral loads (HBVDNAswere 1equal to or greater than×10⁶ IU/mL) were enrolled in our hospital between January 2020 and January 2023, and we randomly assigned them to receive TAF (observation, n=32) or to ETV (control, n=32) therapy. The regimen continued and antiviral efficacy was assessed by end of 12 months. Urine lactulose/mannitol (L/M) ratio was detected by high performance liquid chromatography. Serum D-lactic acid was measured by colorimetry, serum diamine oxidase (DAO) by ultraviolet colorimetry, and serum endotoxin and interleukin-7 (IL-7) levels was assayed by EIISA. Serum procalcitonin (PCT) level was determined by chemiluminescence immunoassay, and heparin-binding protein (HBP) level was detected by immunofluorescence quantitative method. Results By end of 12-month antiviral treatment, complete virological and biochemical responses were obtained in the two groups, and there were no significant differences as respect to serum bilirubin, ALT and AST levels in the two groups (P>0.05); serum DAO, D-lactic acid, endotoxin and urine L/M ratio in the observation group were (2.8±0.6)U/mL, (7.9±1.8)μg/mL, (0.5±0.1)EU/mL and (7.3±1.6)%, all not significantly different compared to [(3.0±0.5)U/mL, (7.8±2.2)μg/mL,(0.6±0.1)EU/mL and (8.1±1.9)%, respectively, P>0.05] in the control; serum PCT, HBP and IL-7 levels were (0.01±0.00)μg/L, (43.1±3.7)ng/mL and (768.9±20.3)pg/mL, also not significantly different as compared to [(0.02±0.01)μg/L,(47.6±3.2)ng/mL and (743.4±21.5)pg/mL, respectively, P>0.05] in the control groups. Conclusion Both TAF or ETV has a satisfactory antiviral efficacy in treatment of patients with compensated hepatitis B-induced LC, without intestinal barrier function damage.

Key words: Liver cirrhosis, Hepatitis B, Tenofovir alafenamide fumarate, Entecavir, High serum viral loads, Intestinal barrier functions, Therapy

李双玲, 刘丽, 陈艺, 李坤. 富马酸丙酚替诺福韦与恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者效果比较研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 749-752.

Li Shuangling, Liu Li, Chen Yi, et al. Intestinal barrier function index changes in patients with compensated hepatitis B cirrhosis and high serum viral loads undergoing tenofovir alafenamide fumarate or entecavir therapy[J]. Journal of Practical Hepatology, 2024, 27(5): 749-752.

参考文献

[1] Nguyen MH, Wong G, Gane E, et al. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev, 2020, 33(2):e00046-19.
[2] Tseng TC, Liu CJ, Yang WT,et al. Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load. Aliment Pharmacol Ther, 2021, 53(8):908-918.
[3] Tseng TC, Liu CJ, Hsu CY,et al. High level of hepatitis B core-related antigen associated with increased risk of hepatocellular carcinoma in patients with chronic HBV infection of intermediate viral load. Gastroenterology, 2019, 157(6):1518-1529,e3.
[4] Zhang T, Yang Y, Wang B,et al. Meta-analysis of influences of Biejiajian pill combined with entecavir on serum liver fibrosis markers of compensatory period of hepatitis b cirrhosis: protocol of systematic review and meta-analysis. Medicine (Baltimore), 2019, 98(51):e18458.
[5] Han Z, Hou H. Editorial: tenofovir disoproxil fumarate and prevention of mother-to-child transmission ofHepatitis B virus. Aliment Pharmacol Ther, 2019, 50(6):707-708.
[6] Lau G, Yu ML, Wong G,et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int, 2021, 15(5):1031-1048.
[7] Ou H, Yuan D, Bi Y, et al. Hepatitis B virus X protein promotes vimentin expression via LIM and SH3 domain protein 1 to facilitate epithelial-mesenchymal transition and hepatocarcinogenesis. Cell Commun Signal, 2021, 19(1):33.
[8] 黄俊榕,吴昌儒,吴健林. 恩替卡韦联合甘草酸二铵治疗慢性乙型肝炎患者效果研究. 实用肝脏病杂志,2022,25(3):327-330.
[9] Liao Q, Wen J, Jiang K, et al. Kushenin combined with adefovir dipivoxil or entecavir for chronic Hepatitis B: asystematic review and Meta-Analysis. Evid Based Complement Alternat Med, 2021, 2021:8856319.
[10] 王帅,陈蕾,张宁,等.FGF-23基因多态性与乙型肝炎病毒感染孕妇应用富马酸丙酚替诺福韦阻断效果的关联.中华医院感染学杂志,2023,33(10):1545-1549.
[11] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2022年版).实用肝脏病杂志,2023,26(3)S18-39.
[12] Liu Y, Guo W, Li M. Diammoniumglycyrrhizinate preparation for Liver function recovery in chronic hepatitis B in China: a Meta-analysis with trial sequential analysis. Curr Pharm Des, 2022, 28(25):2089-2112.
[13] Yuan J, Peng Y, Hao FB,et al. No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis. Aging (Albany NY), 2021, 13(5):7147-7165.
[14] Choi WM, Yip TC, Wong GL,et al. Hepatocellular carcinoma risk in patients with chronic Hepatitis B receiving tenofovir- vs. entecavir-based regimens: individual patient data meta-analysis. J Hepatol, 2023, 78(3):534-542.
[15] Gharehbeglou M, Yazdani S, White K, et al. Atorvastatin rapidly reduces hepatitis B viral load in combination with tenofovir: aprospective clinical trial. Can J Infect Dis Med Microbiol, 2022 ,2022:3443813.
[16] Lim YS, Seto WK, Kurosaki M,et al. Review article: switching patients with chronic Hepatitis B to tenofovir alafenamide-a review of current data. Aliment Pharmacol Ther, 2022, 55(8):921-943.
[17] Li FC, Fan YC, Li YK,et al. Plasma diamine oxidase level predicts 6-month readmission for patients with Hepatitis B virus-related decompensated cirrhosis. Virol J, 2019, 16(1):115.
[18] 胡艳艳,叶晓云,俞巧燕.乙型肝炎肝硬化合并自发性细菌性腹膜炎PCT和HBP与IL-7表达水平.中华医院感染学杂志,2021,31(2):184-187.
[19] Agarwal K, Brunetto M, Seto WK,et al. 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for Hepatitis B virus infection. J Hepatol, 2018, 68(4):672-681.
[20] Zheng W, Liang X, Shui L,et al. Serum procalcitonin correlates with renal function in Hepatitis B virus-related acute-on-chronic liver failure. Cell Physiol Biochem, 2018, 50(5):1794-1803.
[21] Hsu YC, Yeh ML, Wong GL, et al. Incidences and determinants of functional cure during entecavir or tenofovir disoproxil fumarate for chronic Hepatitis B. J Infect Dis, 2021, 224(11):1890-1899.

富马酸丙酚替诺福韦与恩替卡韦治疗高血清病毒载量的代偿期乙型肝炎肝硬化患者效果比较研究^*

Intestinal barrier function index changes in patients with compensated hepatitis B cirrhosis and high serum viral loads undergoing tenofovir alafenamide fumarate or entecavir therapy

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	韦新焕, 柳雅立, 张晶, 贾继东. 代谢相关性脂肪性肝硬化诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(5): 641-645.
[2]	张志强, 方坚, 李东良. 介入治疗肝硬化门静脉高压症研究进展与挑战^*[J]. 实用肝脏病杂志, 2024, 27(5): 650-653.
[3]	中国医药生物技术协会慢病管理分会肝病学组. 双环醇防治肝脏炎性损伤多学科专家共识[J]. 实用肝脏病杂志, 2024, 27(5): 659-668.
[4]	彭麟, 杨春, 李兴泉. 聚乙二醇干扰素α-2b联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 677-680.
[5]	冉书容, 刘洋, 雷兰. 恩替卡韦经治的慢性乙型肝炎患者发生低病毒血症危险因素及转换TAF治疗疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 681-684.
[6]	黎防, 杨宏飞, 张青. 索非布韦联合雷迪帕韦治疗慢性丙型肝炎患者疗效评价^*[J]. 实用肝脏病杂志, 2024, 27(5): 685-688.
[7]	刘雅光, 胡连智, 董一侠, 刘洋. 抗病毒治疗的基因1b型慢性丙型肝炎患者疗效及其血清γ-干扰素和白细胞介素-10水平变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 689-692.
[8]	莫伟斌, 张清友, 黄晓涵, 欧阳婉爱. 达诺瑞韦联合拉维达韦治疗慢性丙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 693-696.
[9]	高怡, 沈小雪, 夏素芹, 张洁, 朱先兰. 自身免疫性肝炎和原发性胆汁性胆管炎患者血清胆汁酸成分变化及其对治疗应答的影响^*[J]. 实用肝脏病杂志, 2024, 27(5): 709-712.
[10]	蒋叶舟, 花霞, 陈国飞, 朱青蓝, 蔡明月. 自身免疫性肝炎患者血清瘦素、外周血调节性T细胞和Th17细胞水平变化^*[J]. 实用肝脏病杂志, 2024, 27(5): 713-716.
[11]	朱家瑞, 葛绍锋, 叶桂云, 黄远茂. 自身免疫性肝炎患者外周血NLR和nCD64指数变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2024, 27(5): 717-720.
[12]	王燕燕, 周桐桐, 卞兆连. 原发性胆汁性胆管炎和原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征患者临床与肝组织病理学特点分析^*[J]. 实用肝脏病杂志, 2024, 27(5): 721-724.
[13]	王秀娟, 朱贺, 张茹梦, 常文绘, 刘玉玉. 泼尼松联合硫唑嘌呤治疗自身免疫性肝炎患者不同减量方法的效果研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 729-732.
[14]	信亮亮, 温智. 2D-SWE技术联合FIB-4和血清VEGF水平评估乙型肝炎肝硬化患者食管静脉曲张价值研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 737-740.
[15]	李瑞妮, 王莎莎, 贾泽博, 韦晓洁, 王腾. 聚桂醇和蛇毒血凝酶注射配合内镜下套扎治疗乙型肝炎肝硬化并发EVB患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 741-744.